drugset

drugset / Trial / NCT05730725

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

NCT05730725 ↗

Phase 2 Completed 109 enrolled Bristol-Myers Squibb

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

Timeline

Start: 2023-04-03
Primary completion: 2024-08-06
Completion: 2024-08-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LOMECITINIB	Small molecule	—	—

Indications